Report: Ex-Merck staffer working on insider-trading plea deal

Zachary Zwerko, the former Merck ($MRK) analyst caught up in an SEC investigation of insider trading, is reportedly working on a plea deal with prosecutors, according to Reuters. Zwerko and an old buddy allegedly worked up the scheme ahead of Merck's $3.9 billion buyout of Idenix last year. The SEC says he also passed on insider info regarding Ardea and ViroPharma. The SEC says the two made at least $722,000 from the scheme, setting up Zwerko for a charge that could have put him behind bars for 5 years. Story

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.